DOCSLIB.ORG

Vaccine Injury Redress Programmes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccine Injury Redress Programmes Vaccine injury redress programmes An evidence review Authors: Martin Keane Tonya Moloney Caitriona Lee Michael O’Sullivan Jean Long March 2019 Disclaimer Any views expressed in this report are those of the authors and not necessarily those of the Minister for Health, the Department of Health or the Health Research Board. Published by: Health Research Board, Dublin © Health Research Board 2019 t 353 1 234 5000 f 353 1 661 2335 e [email protected] w www.hrb.ie Table of Contents TABLE OF CONTENTS .......................................................................................................................... 1 LIST OF TABLES .......................................................................................................................................... 4 LIST OF FIGURES ........................................................................................................................................ 4 ABBREVIATIONS ........................................................................................................................................ 5 EXECUTIVE SUMMARY ....................................................................................................................... 6 PURPOSE ................................................................................................................................................. 6 REVIEW QUESTIONS ................................................................................................................................... 6 METHODS ................................................................................................................................................ 6 KEY FINDINGS ........................................................................................................................................... 7 New Zealand ..................................................................................................................................... 7 Nordic countries ................................................................................................................................ 8 Asian countries ................................................................................................................................. 8 USA ................................................................................................................................................... 9 UK ..................................................................................................................................................... 9 1 INTRODUCTION ........................................................................................................................ 11 1.1 PURPOSE OF THE REVIEW .............................................................................................................. 11 1.2 RESEARCH QUESTIONS .................................................................................................................. 12 1.3 BACKGROUND ............................................................................................................................. 12 Approaches to vaccine injury .......................................................................................... 12 Arguments for and against compensation programmes ................................................ 12 Key characteristics of existing schemes .......................................................................... 13 2 METHODS ................................................................................................................................. 25 2.1 INTRODUCTION ........................................................................................................................... 25 2.2 LITERATURE SEARCH AND SELECTION PROCESS ................................................................................... 25 Outline to the search process ......................................................................................... 25 Search terms used ........................................................................................................... 26 Search engines and databases........................................................................................ 26 Supplementary searches ................................................................................................. 26 Title/abstract screening .................................................................................................. 27 Full-text screening ........................................................................................................... 27 2.3 DATA REDUCTION AND EXTRACTION ................................................................................................ 29 2.4 DATA ANALYSIS ........................................................................................................................... 30 Method employed to analyse data ................................................................................. 30 The steps we took to undertake constant comparative analysis .................................... 31 2.5 DATA EVALUATION AND RELEVANCE ................................................................................................ 32 2.6 STRENGTHS AND WEAKNESSES OF OUR METHODS ............................................................................... 33 3 FINDINGS ................................................................................................................................. 34 3.1 INTRODUCTION ........................................................................................................................... 34 3.2 NEW ZEALAND ............................................................................................................................ 34 Introduction .................................................................................................................... 34 Question 1: What design features and/or contextual conditions are thought to impact on the operating costs associated with no-fault vaccine damage schemes? ................................. 35 Question 2: What design features and/or contextual conditions are thought to impact on timely access to no-fault vaccine damage schemes? ................................................................ 35 Question 3: What design features and/or contextual conditions are thought to impact on the number of applicants seeking redress via no-fault vaccine damage schemes? .................. 38 Question 4: What design features and/or contextual conditions are thought to impact on the volume and costs of awards made under no-fault vaccine damage schemes? ................... 38 1 Question 5: Do no-fault vaccine damage schemes enjoy public acceptance? ................ 40 Question 6: What cost-control mechanisms covering no-fault vaccine damage schemes are reported in the literature? ........................................................................................................ 41 Summary ......................................................................................................................... 42 3.3 NORDIC COUNTRIES ..................................................................................................................... 43 Introduction .................................................................................................................... 43 Denmark ......................................................................................................................... 43 Finland ............................................................................................................................ 49 Norway ........................................................................................................................... 56 Sweden ........................................................................................................................... 60 3.4 ASIA .......................................................................................................................................... 67 Introduction .................................................................................................................... 67 China ............................................................................................................................... 67 Japan ............................................................................................................................... 75 Korea ............................................................................................................................... 79 Taiwan ............................................................................................................................ 84 3.5 UNITED STATES OF AMERICA ......................................................................................................... 90 Introduction .................................................................................................................... 90 Question 1: What design features and/or contextual conditions are thought to impact on the operating costs associated with no-fault vaccine damage schemes? ................................. 90 Question 2: What design features and/or contextual conditions are thought to impact on timely access to no-fault vaccine damage schemes? ................................................................ 92 Question 3: What design features and/or contextual conditions are thought to
Load more

Recommended publications
  • Considerations for Causality Assessment of Neurological And
    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
    [Show full text]
  • Open Letter From: UK Medical Freedom Alliance To
    Open Letter From: UK Medical Freedom Alliance To: The Medicines and Healthcare products Regulatory Agency (MHRA) To: The Joint Committee on Vaccination and Immunisation (JCVI) Cc: Matt Hancock (Secretary of State for Health and Social Care) Re: Advertisement, Offer and Administration of Vaccines for COVID-19 in the UK Sent by Email on 23 November 2020 To All Concerned: CONCERNS AND SUGGESTIONS REGARDING THE UK’S COVID-19 VACCINE AGENDA We are an alliance of medical practitioners, scientists, academics and lawyers who are concerned about the current climate surrounding the impending use of a possible vaccine (“a Covid Vaccine”) that may be advertised, offered and administered among the general public in response to the recent pandemic that has been attributed to a virus called SARS- CoV-2, which we are told causes the symptoms of a disease called COVID-19. In this letter we outline our concerns and highlight some of the potential negative outcomes that could arise if these concerns are not taken seriously. We also offer some suggestions for your consideration. These practical suggestions may help avert, or alleviate, some of the negative impacts that are likely to result if no action is taken and the current vaccine agenda continues unchecked. Our Concerns about a Covid Vaccine, at the present time (and subject to additions or amendments as the situation progresses) fall into the following four areas: I) Over-Estimation of the Public Health Risk from SARS-CoV-2 II) Inadequate Assessment of the Public Health Risk from a Covid Vaccine III) Medical Freedom and Informed Consent IV) Media Claims and Misinformation These are explained in detail below.
    [Show full text]
  • COVID-19 Vaccination in the UK and Ireland: Ethics in Practice
    COVID-19 Vaccination in the UK and Ireland: Ethics in Practice Clayton Ó Néill, Mary-Elizabeth Tumelty, Mary Donnelly, Anne-Maree Farrell, Rhiannon Frowde and Linda Pentony PHELN Workshop Paper No. 1, June 2021 COVID-19 VACCINATION IN THE UK AND IRELAND ETHICS IN PRACTICE PHELN WORKING PAPER NO. 1, JUNE 2021 Clayton Ó Néill, Mary-Elizabeth Tumelty, Mary Donnelly, Anne-Maree Farrell, Rhiannon Frowde and Linda Pentony1 Research for the workshop paper was undertaken as part of the Public Heath Ethics and Law Research Network project, which is is jointly funded by the Economic and Social Research Council (ES/V009222/1) and the Irish Research Council (IRC/V009222/1). The support of the ESRC and the IRC is gratefully acknowledged. 1 Lead authors (A-Z): Dr Clayton Ó Néill (Queen’s University Belfast) and Dr Mary-Elizabeth Tumelty (University College Cork) were involved in the conception and design of the workshop paper; drafting the paper and revising it; providing intellectual content of critical importance and final approval of the version to be published. Other authors (A- Z): Professor Mary Donnelly (University College Cork) and Professor Anne-Maree Farrell (University of Edinburgh) were involved in providing important intellectual content to the workshop paper and final approval of the version to be published. Ms Rhiannon Frowde (University of Edinburgh) and Ms Linda Pentony (University College Cork) provided intellectual content through research undertaken in the preparation of appendices to the workshop paper. 1 COVID-19 VACCINATION IN THE UK AND IRELAND: ETHICS IN PRACTICE PHELN WORKING PAPER NO. 1, JUNE 2021 TABLE OF CONTENTS OVERVIEW …………………………………………………..………………………………………………………………………………………………3 PART I: COVID-19 VACCINE DEVELOPMENT AND ADMINISTRATION ………….…..….……………………………..………….3 PART II: COVID-19 VACCINATION IN THE UK ………………………………………………..………………………………………………..4 i.
    [Show full text]
  • Vaccine a Vaccine Is a Biological Preparation That Provides Active Acquired Immunity to a Particular Disease
    Vaccine A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated). The administration of vaccines is called vaccination. Vaccination is the most effective method of preventing infectious diseases;]widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox and the restriction of diseases such as polio, measles, and tetanus from much of the world. The effectiveness of vaccination has been widely studied and verified; for example, vaccines that have proven effective include the influenza vaccine, the HPV vaccine, and the chicken pox vaccine. The World Health Organization (WHO) reports that licensed vaccines are currently available for twenty-five different preventable infections. The terms vaccine and vaccination are derived from Variolae vaccinae (smallpox of the cow), the term devised by Edward Jenner to denote cowpox. He used it in 1798 in the long title of his Inquiry into the Variolae vaccinae known as the Cow Pox, in which he described the protective effect of cowpox against smallpox.
    [Show full text]
  • A Comparative Analysis of Vaccine Injury Compensation in the United States and Great Britain Rob Henson
    Tulsa Journal of Comparative and International Law Volume 15 | Issue 1 Article 9 9-1-2007 Inoculated against Recovery: A Comparative Analysis of Vaccine Injury Compensation in the United States and Great Britain Rob Henson Follow this and additional works at: http://digitalcommons.law.utulsa.edu/tjcil Part of the Law Commons Recommended Citation Rob Henson, Inoculated against Recovery: A Comparative Analysis of Vaccine Injury Compensation in the United States and Great Britain, 15 Tulsa J. Comp. & Int'l L. 61 (2007). Available at: http://digitalcommons.law.utulsa.edu/tjcil/vol15/iss1/9 This Casenote/Comment is brought to you for free and open access by TU Law Digital Commons. It has been accepted for inclusion in Tulsa Journal of Comparative and International Law by an authorized administrator of TU Law Digital Commons. For more information, please contact daniel- [email protected]. INOCULATED AGAINST RECOVERY: A COMPARATIVE ANALYSIS OF VACCINE INJURY COMPENSATION IN THE UNITED STATES AND GREAT BRITAIN Rob Henson* I. INTRODUCTION Vaccination against infectious disease is hailed as one of the ten greatest public health achievements of the twentieth century.1 When the twentieth century began, 160 of every 1000 children born in the United States died from an infectious disease before their fifth birthday. 2 At the dawn of the twenty-first century, many life-threatening infectious diseases have been nearly eradicated by childhood vaccination. 3 Children in the United States are prohibited from attending school until they have received all of the required vaccinations.4 The typical diseases vaccinated against in the United States are polio, diphtheria, pertussis, tetanus, measles, mumps, rubella, congenital rubella syndrome, smallpox, influenza, hepatitis B, varicella (chicken pox), Haemophilus influenzae type b (hereinafter Hib), and pneumococcal disease.
    [Show full text]
  • Designing a No-Fault Vaccine-Injury Compensation Programme for Canada: Lessons Learned from an International Analysis of Programmes
    MUNK SCHOOL BRIEFINGS February 2011 Designing a No-Fault Vaccine-Injury Compensation Programme for Canada: Lessons Learned from an International Analysis of Programmes By Jennifer Keelan PhD Dalla Lana School of Public Health, University of Toronto Comparative Program on Health and Society Review Committee, 2006- Comparative Program on Health and Society Post-doctoral Fellow, 2005-6 and Kumanan Wilson MSc, FRCP(C) Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa For the CIHR funded Canadian No-Fault Compensation for Vaccine-related Injuries Working Group MUNK SCHOOL BRIEFINGS Designing a No-Fault Vaccine-Injury Compensation Programme for Canada: Lessons Learned from an International Analysis of Programmes By Jennifer Keelan PhD (1) Kumanan Wilson MSc , FRCP(C) (2) For the CIHR funded Canadian No-Fault Compensation for Vaccine-related Injuries Working Group Correspondence: Dr. Kumanan Wilson The Ottawa Hospital, Civic Campus 1053 Carling Avenue Administrative Services Building, Room 1009, Box 684 Ottawa, ON K1Y 4E9 [email protected] No-fault Compensation for Vaccine-Related Injuries Working Group: Professor Jennifer Keelan, Dr. Kumanan Wilson, Professor Amir Attaran, Dr. Jason Busse, Dr. Murray Krahn, Dr. Allison McGeer, Dr. Ross Upshur. (1) Dalla Lana School of Public Health, University of Toronto; CPHS Review Committee, 2006-; CPHS Post-doctoral Fellow, 2005-6 (2) Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa MUNK SCHOOL OF GLOBAL AFFAIRS UNIVERSITY OF TORONTO Munk School of Global Affairs At Trinity College University of Toronto 1 Devonshire Place Toronto, Ontario, Canada M5S 3K7 Telephone: (416) 946-8900 Facsimile: (416) 946-8915 E-mail: [email protected] Website: www.munkschool.utoronto.ca © Jennifer Keelan PhD, Kumanan Wilson MSc, FRCP(C) 978-0-7727-0847-2 ISSN 1715-3484 The University of Toronto’s Munk School of Global Affairs is a hub for specialists in global affairs, providing innovative approaches to the challenges, organizations, and ideas that are at the frontiers of knowledge.
    [Show full text]
  • Ontario Vaccine Deliberation
    Ontario Vaccine Deliberation OCTOBER 2017 DISCOURSE, SCIENCE, PUBLICS UNIVERSITY OF GUELPH ONTARIO VACCINE DELIBERATION This booklet was prepared by the Ontario Vaccine Deliberation research team (listed in alphabetical order): Lucie Marisa Bucci Michael Burgess Apurv Chauhan Sara Crann Maya Goldenberg Meghan McMurtry Kieran O’Doherty Wade Pickren Don Willison October, 2017 Guelph, Ontario, Canada 2 ONTARIO VACCINE DELIBERATION What is the Purpose of this Booklet? This booklet is meant to stimulate and inform discussion and reflection for the Ontario Vaccine Deliberation. While it includes a variety of perspectives, it cannot encompass the diversity of all possible perspectives. Reading it is the first step of being involved in a 4-day public deliberation event on childhood vaccination in Ontario (see What is a public deliberation? on page 4). This booklet is not intended to be either for or against vaccines. In this booklet, you will find information on a range of issues related to childhood vaccination, such as history about the development of vaccines, the science behind vaccines, and both the good that has come from vaccines as well as some of the things that have gone wrong with vaccines. The information presented in this booklet, and the discussions that will take place in October, are focused on early childhood vaccinations (see Ontario’s publicly- funded immunization schedule on page 11). People draw on different types of information to support their opinions. There is a range of available information about vaccines on the Internet, in the media, in academic journals and other sources, and it is difficult to know which information to trust.
    [Show full text]
  • Vaccines & Public Health
    June 2004 Number 219 VACCINES & PUBLIC HEALTH Public anxiety over the MMR vaccine led to decreased Benefits of vaccination MMR uptake and a rise in measles cases. Although As well as providing protection to individuals, latest figures suggest this trend may be changing, public immunisation confers wider protection. It can benefit concerns about vaccination could affect the future those not able to be immunised (such as those who are success of immunisation programmes. This POSTnote too young, or have weak immune systems) by reducing summarises trends in outbreaks of disease and vaccine risk of exposure from the rest of the population. Rubella uptake within the UK. Issues addressed include public vaccine is given to both boys and girls to reduce the attitudes, vaccine availability and vaccine safety. circulation of the virus in children, thus lowering the chance of pregnant women (the group most at risk from Infectious disease the virus) contracting rubella.1 MMR vaccine has greatly The emergence of new diseases, the resurgence of known reduced the number of congenital rubella cases. 2 diseases, global travel, and increased numbers of people with weak immune systems (e.g. due to cancer Safety of vaccination treatment, organ transplants or HIV/AIDS) all provide As with any other medical intervention, vaccination is not opportunities for infectious diseases to develop and entirely free from risk. All vaccines may have some spread. Although most infections are short-lived and adverse effects. These are usually minor, such as local cause no long-term problems, they are a major cause of reactions at the site of the injection or a slight fever, but hospital admissions and can have serious complications.
    [Show full text]
  • For Whose Benefit? Transparency in the Development and Procurement of COVID-19 Vaccines
    Transparency International (TI) is the world’s leading non-governmental anticorruption organisation, addressing corruption in its many forms through a network of more than 100 national chapters worldwide. Transparency International Global Health’s overall goal is to improve global health and healthcare outcomes for the benefit of all people, of all ages. It aims to achieve this by reducing corruption and promoting transparency, integrity and accountability within the pharmaceutical and healthcare sectors. The World Health Organization Collaborating Centre (WHO CC) for Governance, Accountability, and Transparency in the Pharmaceutical Sector was established in 2015 at the Leslie Dan Faculty of Pharmacy, University of Toronto. The WHO CC assembles leading governance and related experts who have created a collaborative network to support WHO policy and country operations on the global problem of corruption. Acknowledgements: We would like to thank Till Bruckner, Joel Lexchin, Karen Hussman, Sarah Steingrüber, Klaus Munkholm, Asger San Paludan-Müller, Emma Sydenham, and Emma Thompson for providing invaluable insights and comments. Design: Colin Foo Report team: Natalie Rhodes (TI GH), Tom Wright (TI GH), Violet Rusu (WHO CC), Hela Bakhtari (WHO CC), Jonathan Cushing (TI GH), Jillian Kohler (WHO CC). Images: Page 10, 16, 25, 30, 32, 34 © Rawpixel.com / Adobe Stock, Page 21 © Tom Merton / Caia Image / Adobe Stock. © 2021 Transparency International. All rights reserved. Reproduction in whole or in parts is permitted, providing that full credit is given to Transparency International and provided that any such reproduction, in whole or in parts, is not sold or incorporated in works that are sold. Written permission must be sought from Transparency International if any such reproduction would adapt or modify the original content.
    [Show full text]
  • Multiple Choice Answers on Immunisation Against Infectious Disease the Green Book
    Multiple Choice Answers on Immunisation against Infectious Disease The Green Book Original version issued February 2008 Updated version December 2017 Health Protection Team – MCQs on the Green Book - Answers Contents – Answers Chapter 1 – Immunity and How Vaccines Work Answers 3 Chapter 2 – Consent Answers 4 Chapter 3 – Cold Chain Answers 5 Chapter 4 – Immunisation Procedures Answers 6 Chapter 5 – Immunisation by Nurses and Other Professionals Answers 7 Chapter 6 – Contraindications Answers 8 Chapter 7 – Immunisation of Those with Underlying Medical Conditions Answers 9 Chapter 8 – Vaccine Safety and Adverse Events Following Immunisation Answers 10 Chapter 9 – Surveillance and Monitoring for Vaccine Safety Answers 11 Chapter 10 – Vaccine Damage Payment Scheme Answers 12 Chapter 11 – Immunisation Schedule Answers 13 Chapter 12 – Immunisation of Healthcare and Laboratory Staff Answers 15 Chapter 13 – Anthrax Answers 16 Chapter 14 – Cholera Answers 17 Chapter 15 – Diphtheria Answers 18 Chapter 16 – Haemophilus Influenza Type B (Hib) Answers 19 Chapter 17 – Hepatitis A Answers 20 Chapter 18 – Hepatitis B Answers 21 Chapter 18a – Human Papillomavirus (HPV) Answers 23 Chapter 19 – Influenza Answers 24 Chapter 20 – Japanese Encephalitis (JE) Answers 26 Chapter 21 – Measles Answers 27 Chapter 22 – Meningococcal Answers 28 Chapter 23 – Mumps Answers 30 Chapter 24 – Pertussis Answers 31 Chapter 25 – Pneumococcal Answers 32 Chapter 26 – Polio Answers 34 Chapter 27 – Rabies Answers 35 Chapter 27a – Respiratory Syncytial Virus (RSV) Answers 36 Chapter
    [Show full text]
  • Vaccine Access and Uptake
    Vaccine access and uptake SUMMARY • Vaccine uptake can be a ‘default’ or a proactive programmes or policies that make vaccination decision, and can be influenced by a range of mandatory or a condition of access to factors, including how people understand and institutions, services, or employment. weigh up benefits and risks; where they receive • Ethical considerations for public health information and guidance about vaccines; authorities include promoting good health and personal beliefs or values; and practical reducing the burden of disease; balancing considerations. individual, community and wider public • Public health authorities use different strategies interests; fair and effective use of public to increase participation in vaccination resources; and international obligations and programmes, including information or global health security. educational campaigns; and incentivised INTRODUCTION Most countries have vaccination programmes as widely accepted. Declining confidence in vaccines, part of their public health agenda, with support sometimes referred to as ‘vaccine hesitancy’, has from global agencies.1 Vaccines targeting more than been declared a major health threat by the WHO.4 20 life-threatening diseases are currently in use, some reaching over 85% of their target population.2 This briefing note explores factors influencing However, vaccine coverage is highly uneven at a the access and uptake of vaccines; the different global level.3 There are also concerns about a loss of approaches taken by public health authorities to
    [Show full text]
  • Pigs Don't Fly and You Cannot Expect Absolutely Safe COVID-19 Vaccines
    European Journal of Health Law 28 (2021) 165–183 brill.com/ejhl Pigs Don’t Fly and You Cannot Expect Absolutely Safe COVID-19 Vaccines (But You Should Expect a Fair Compensation) Vera Lúcia Raposo | ORCID: 0000-0001-7895-2181 Faculty of Law, University of Macau, Macau, China [email protected], [email protected] Abstract This paper focuses on the COVID-19 vaccines authorised for use in the European Union, and explores the mechanisms in place to control vaccine safety and to com- pensate injured patients, mainly in the context of European law. Based on these con- siderations, the paper concludes that the refusal by some potential vaccinees to take the vaccine based on safety concerns is ungrounded and an indication of unrealistic expectations, but that in order to build public trust proper compensation mechanisms should be in place. Keywords COVID-19 – compensation – drug safety – drug approval – pharmacovigilance – vaccines. 1 Introduction Whether it comes as a surprise or not, many people do not want to get vaccinated against COVID-19 with the available vaccines1 (this paper uses ‘COVID-19 vaccines’ to refer to the various vaccines approved or under devel- opment to protect against the disease caused by the SARS-Cov-2 virus). 1 R. Tucker, ‘Approximately a Fifth of People Across the World Would Refuse a COVID-19 Vaccine’, Hospital Healthcare Europe (14 December 2020), available online at https://hospi talhealthcare.com/covid-19/approximately-a-fifth-of-people-across-the-world-would -refuse-a-covid-19-vaccine/ (retrieved 20 January 2021). © Koninklijke Brill NV, Leiden, 2021 | doi:10.1163/15718093-bja10042Downloaded from Brill.com09/26/2021 08:06:31PM via free access 166 Raposo Vaccination is essential to build herd immunity to control the pandemic, espe- cially considering that 80% of infected individuals are asymptomatic,2 and a significant number of infections (between 40% to 50%) occur before the onset of the first symptoms.
    [Show full text]